Plasminogen–fibrin complex (PLG-Fibrin)

The fibrin-bound plasminogen complex is the essential molecular assembly that initiates fibrinolysis, the physiological process of blood clot dissolution. Plasminogen, a zymogen synthesized in the liver, binds to fibrin fibers through its lysine-binding sites (LBS) located within its kringle domains [UniProt P00747]. This binding is a prerequisite for efficient fibrinolysis, as it brings plasminogen into close proximity with its primary activator, tissue-type plasminogen activator (tPA), which also possesses high affinity for fibrin [PubMed: 11919084]. The resulting ternary complex (fibrin-tPA-plasminogen) accelerates the conversion of plasminogen to the active protease plasmin by several orders of magnitude compared to the reaction in solution [StatPearls: Thrombolytic Therapy]. This localized activation ensures that proteolytic activity is restricted to the thrombus, minimizing systemic degradation of fibrinogen and other clotting factors. Pharmacologically, this interface is targeted by thrombolytic agents like alteplase to dissolve pathological clots in conditions such as ischemic stroke and myocardial infarction [FDA Label: Activase]. Conversely, antifibrinolytic agents like tranexamic acid act by competitively blocking the lysine-binding sites on plasminogen, preventing its interaction with fibrin and thereby inhibiting clot breakdown in surgical or traumatic bleeding [StatPearls: Tranexamic Acid].

Other names

Fibrin-bound plasminogenPlasminogen–fibrin interfaceFibrin-plasminogen-tPA ternary complex

Thrombolytic agents (plasminogen activators) enhance the conversion of fibrin-bound plasminogen into active plasmin within the thrombus, whereas antifibrinolytic agents competitively inhibit the lysine-binding sites on plasminogen to prevent its recruitment to the fibrin matrix.